Physician profile
Heather L Norton
NPI 1720047517
$57,165.87
in general payments reported to CMS, 2019-2025
56 companies · $7,939 in 2025
The $7,939 reported for 2025 was more than what 99% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $18K · 2022: $15K · 2023: $7,736 · 2024: $8,656 · 2025: $7,939.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Food and Beverage: $5,529 · Travel and Lodging: $14.41.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,787.50 |
| Food and Beverage | $5,529.03 |
| Travel and Lodging | $14.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $48,843.41 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $556.76 | 2021-2025 | |
| Sk Life Science, INC. | $472.85 | 2022-2024 | |
| Acadia Pharmaceuticals INC | $421.47 | 2022-2025 | Nuplazid |
| Abbott Laboratories | $406.71 | 2021-2025 | Amplatzer Amulet |
| Biogen, INC. | $376.72 | 2021-2025 | Tysabri, Vumerity, Leqembi |
| Amneal Pharmaceuticals LLC | $354.00 | 2021-2025 | Rytary, Crexont |
| Neurocrine Biosciences, INC. | $352.08 | 2021-2025 | Ingrezza, Ongentys |
| Janssen Pharmaceuticals, INC | $339.87 | 2021-2023 | Ponvory |
| Lundbeck LLC | $336.58 | 2021-2025 | Vyepti, Rexulti |
| Teva Pharmaceuticals USA, INC. | $332.42 | 2021-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Celgene Corporation | $285.17 | 2021-2023 | Zeposia |
| Genzyme Corporation | $282.84 | 2021-2025 | |
| Pfizer INC. | $251.25 | 2021-2025 | |
| Argenx US, INC. | $218.95 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Norton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.